issu lli loxo pro-forma model reflect combin compani despit
lower ep estim thru long-stand posit view
strengthen loxo supplement pipelin anoth high-potenti asset
last week announc acquisit loxo oncolog cash
loxo share net exist loxo cash transact subject
financ condit expect close loxo recent approv
vitrakvi larotrectinib inhibitor partnership bayer launch
ret inhibitor expect file late previously-issu financi
guidanc updat earn call februari state
increment expect total acquisit
alreadi assum previously-provid guidanc reiter financi
expect expect deal accret cash basi start
integr loxo model assum close ep estim
lower
ep project increas
ep compound-annual-growth-rate remain better averag versu
previous
cowen biotech team last publish sale forecast
ad model includ non-gaap revenu loxo/bay
collabor product vitrakvi pend clariti account treatment
acquisit visibl bayer chang control intent determin
whether remain co-promot partner bayer gain exclus right earn
royalti sale collabor product state contempl scenario
arriv acquisit price think littl chanc deal break
chang control bayer captur full right would allow avoid pay
certain develop market expens front would garner less profit
road scenario revers true either scenario
profit stream seem substanti differ
sale estim unchang near-term howev sale forecast
rais
model reflect increas month
sg increas
loxo acquisit financ combin cash debt assum
take debt interest result translat
year increment interest expens model reflect total
non-oper expens
pleas see page report import disclosur
number promis new drug current roll hand late-stag agent
pois launch next year strengthen loxo asset give us
confid above-averag sale ep growth prospect estim ep
compound-annual-growth-rate compar industri averag dividend yield attract
verzenio breast cancer emgal
perform diabet busi
notabl trulic
full trulic rewind data ada
close loxo acquisit
separ elanco
revenu growth leverag
ep growth
declin alimta
temper keytruda/chemo
one four less visibl pipelin
candid gener
margin expans sooner greater
alimta declin rapidli
margin expans delay reduc
compani global biopharmaceut compani incorpor
indiana two main segment human pharmaceut product anim health
product lead product area diabet metabol diseas oncolog
among other lilli anim health busi oper elanco anim
divis develop manufactur market product food companion
anim retain elanco post septemb ipo
compani data cowen compani
grosssg ar dop non-pretaxtaxnetepssharessal chgp mm sl mm slsp opp rateincom dil restat pension account rule chang cowen
compani data cowen compani
productstrul europ lc ex europ lc ex europ lc ex europ lc ex world-wide share europ lc ex world-wide share cowen
compani data cowen compani
compani data cowen compani
compani data cowen compani
compani data cowen compani
compani data cowen compani
compani data cowen compani
healthfood end market sale euro end market sale world-wide share end market sale euro end market sale world-wide share cowen
compani data cowen compani
growth productstrul us share novo competit manageabletrul europ lc ex fx -australia europetrul eu emerg marketstrul qweek dose type diabet rewind cv studi posit data ada higher dose phase expir biosimilar launch new modal anticipatedforteo europ lc ex fx -australia europeforteo expir biosimilar launch anticipatedforteo expir biosimilar launch anticipatedforteo emerg marketsforteo hormon osteoporosi two year durat treatmentcyramza pressur io target agentscyramza europ lc ex fx -australia europecyramza nsclc cyramza uptak gastriccyramza emerg marketscyramza ramu app gastric lung file ph lungjardi us empa-reg cv outcom studi reflect label heart failur studi underwayjardi europ lc ex fx -australia europejardi eu empa-reg data file file jardiance/trajenta nda eujardi japanjardi emerg market approv chinajardi world-wide share inhibitor share gross profit w/bi reflect revenue incl glyxambi synjardi hf type diabet ptrajenta market share patent expir europ lc ex fx -australia europetrajenta patent expir patent expir emerg marketstrajenta world-wide share inhibitor cv outcom data expect share gross profit bi reflect revenu cowen
compani data cowen compani
new drugstaltz psoriasi market share competit landscap evolv rapidlytaltz europ lc ex fx taltz eu mod/sever psoriasi taltz phase axspa radiograph non-radiograph basaglar/abasria settlement w/sni allow launch strong launchbasaglar/abasria europ lc ex fx basaglar/abasria market eubasaglar/abasria countri basaglar/abasria insulin glargin diabet lantu biosimilar expectedglucagon europ lc ex fx gucagon hypoglycemia intranas filedadcirca launch spetmeb europ lc ex fx adcirca pulmonari arteri hypertensionlartruvo soft tissu sarcoma europ lc ex fx lartruvo phase ii pancreat cancer pdgf alpha inhib approv eu/japan mbc adjuv bc inhib ra launch eu japan atop derm sle alopecia areata cgrp mab market episod chronic migrain cluster ha data oral human ant-egfr fda approv line squamou nsclc launch eu cowen
compani data cowen compani
new drug activ ret-mut cancer via loxo acq close sever pain cancer pain oa pain clbp phase safeti data key tx studi posit file oral altern deliveri consid via colucid diagnost tau imag agent phase data rapid act phase dm develop producttgf beta phase amylin calcitonin receptor agonist diabet phase ulcer coliti phase psoriasi phase crohn diseas phase iitau deposit diseas phase iibtk phase phase inhibitor phase inh small molecul cancer phase ii tier develop clarifi data expect sever kinas phase pancreat cancer lung rcc melanoma solid tumor earlier phase select non-coval btk inhibitor b-cell leukemias/lymphoma pi/ii initi via diseas phase iierbitux revenu erbitux sale full right close royalti europ lc ex fx -australia europeerbitux royalti report ou revenu key greater transpar drug solderbitux royalti royalti kgaa asset due fulli paid licenseerbitux royalti growth new drug sale drugsalimta exp pedi extens vitamin supplement patent prevail appeal pto deni ipr vitamin supplement patent approv use keytruda nsclcalimta europ lc ex fx -australia europealimta exp vitamin supplement patent til eu upheld eu gener francealimta exp method-of-us patent eu alimta emerg marketsalimta synthetas inhib mesothelioma nscl io/target agent impact nsclc usageciali expir pedi exclus pend patent litig settlement allow gener launch gener sildenafil pressuringciali europ lc ex fx -australia europeciali expir expir emerg marketsciali bphhumatrop europ lc ex fx -australia europehumatrop emerg marketshumatrop cowen
compani data cowen compani
establish drug continuedeffi expir includ pedi exclus effient europ lc ex fx -australia europeeffi expir emerg marketseffi trilog medic mgd patient accoast pre-tx trigger drug elut stent miss endpointsevista expir multipl gener soldevista europ lc ex fx -australia europeevista expir expir emerg marketsevista breast cancer preventioncymbalta expir multipl gener soldcymbalta europ lc ex fx -australia europecymbalta exclus expir gener launch mid expir emerg marketscymbalta pain gad fibromyalgia chronic painzyprexa expir author gener sale book herezyprexa europ lc ex fx -australia europezyprexa expir expir gener launch emerg marketszyprexa strattera expir europ lc ex fx -australia canada europestrattera expir emerg marketsstrattera deficit hyperactivityprozac europ lc ex fx -australia europeprozac competitionprozac emerg marketsprozac europ lc ex fx -australia europegemzar emerg marketsgemzar nsclc bladder breast ovarian gener cowen
compani data cowen compani
establish drug continuedreopro europ lc ex fx -australia europereopro emerg marketsreopro mix view competit productsaxiron launchedaxiron europ lc ex fx axiron topic solut agreement acrux market eu pursu chf market foreign europ lc ex europeacto emerg marketsacto foreign market pay royalti sale otcor cd outlicens dura antibiot focusinject inject antibiot market share sni biosimilar rcv approv europ lc ex fx -australia europehumalog biosimilar approv eu emerg marketshumalog act insulin patent expir europ lc ex fx -australia europehumulin emerg marketshumulin patent protectionoth productsinsulin hyperlipidemia kowa latin american right retain right patent expir intern product beirsdorf german drug manuf establish drug drug sale new product cowen
compani data cowen compani
compani data cowen compani
anim healthfood nv acquisit close addit jansen sales/yr lohmann sales/yr sales/yr total equiti model assum remaind retainedy/i industri averagey/i trajenta end market sale euro rate end market sale world-wide share inhibitor cv outcom data expect share gross profit bi reflect revenuejardi end market sale euro rate end market sale world-wide share inhibitor share gross profit w/bi reflect revenue incl glyxambi synjardi hf piii type diabet piii cowen
valuat methodolog primarili base current year forward price-to-earnings multipl
also consid total return/p ratio market cap/fre cash flow metric
failur pipelin product intellectu properti challeng econom sensit
price pressur and/or weaken consum demand develop market econom
and/or polit uncertainti emerg market chang tax law outlook
dividend fluctuat foreign exchang rate
risk includ continu success exist portfolio notabl diabet portfolio
success pipelin product especi ramucirumab dulaglutid success
deal patent litig patent expir pressur uncertainti strateg
direct could includ outlook dividend greater expect
competit diabet affect franchis macro factor lessen appeal
